Member Info for Bermudashorts

Really interesting RNS this morning. As the RNS says, disseminated tumour cells can lie dormant in the bone marrow for years. A patient may therefore live seemingly cancer free for years after treatment and then suddenly relapse. They don't yet know the triggers for reactivation of these dormant tumour cells. For those who don't know, adjuvant treatments are those given to patients who have already been treated with primary treatments and are cancer free. An adjuvant treatment is then given to prevent relapse. For breast cancer, this might be hormone treatments whereas for melanoma this is now an expensive immunotherapy checkpoint inhibitor. The difficulty is in knowing which patients to treat. Physicians obviously don't want to continue pumping patients with drugs if they don't have to, especially as in some cases they're highly toxic. Plus of course, there are cost implications. Cancer treatments are rapidly improving and more and more patients will now be surviving so this is a growing problem. So you can see that a liquid biopsy showing whether the patient's bone marrow is a reservoir for dormant tumour cells could be a really useful tool in deciding whether that patient should be given an adjuvant treatment or not. Not only that, but analysis of the tumour cell could also help to decide the best treatment to give. Good stuff. https://investegate.co.uk/angle-plc--agl-/rns/parsortix-harvests-cancer-cells-from-bone-marrow/201710230700032654U/

"Surgical bleeding is a common problem that can be associated with significant blood loss, increasing patient morbidity and mortality. PeproStat works fast and has shown to reduce the non-responder rate by almost 50% compared to a current standard of care product. This provides surgeons with a huge and clinically relevant advantage in providing better control of excess bleeding during surgery and could be hugely beneficial to patients" https://investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-s-peprostat-reports-positive-results/201710230700042686U/ "

There are two types of liquid biopsy. The first is a circulating tumour DNA (ctDNA) biopsy. It's thought that when tumour cells die, they release tiny fragments of DNA into the bloodstream and ctDNA liquid biopsies aim to capture these fragments. This is the type of liquid biopsy that Grail are developing. The second type of liquid biopsy is a circulating tumour cell (CTC) biopsy. As cancer spreads, whole tumour cells are released into the bloodstream and travel around the body to new locations. CTC liquid biopsies attempt to capture whole, live tumour cells. Angle's Parsortix system is a CTC liquid biopsy. Capturing whole tumour cells is extremely difficult, not least because they are so rare - it's thought one in a billion cells. As you can imagine though, scientists can get far more information from a whole, live, undamaged tumour cell than just a fragment of its DNA. So to answer your original question, although they are both operating in the same field, Grail and Angle are developing completely different types of liquid biopsy. You really can't compare them, other than to say that the Parsortix system allows researchers and clinicians to carry out a much broader range of downstream analyses.

Another excellent RNS. "The ParsortixTM system out-performed all the other systems on all the measures investigated and was recommended by the investigators as the system to use in patients with such renal cell carcinomas. In particular, the ParsortixTM system had both the highest cell recovery and the highest purity of all the approaches studied." https://investegate.co.uk/angle-plc--agl-/rns/angle--7th-peer-reviewed-publication-on-parsortix/201710170700067443T/

Good to see Redx attending Bio Europe next month in Berlin. https://ebdgroup.knect365.com/bioeurope/ Also good to see big pharma returning to development of new antibiotics and prepared to pay for them. https://endpts.com/roche-ties-a-387m-knot-with-warp-drive-bio-in-collaboration-spotlighting-new-classes-of-antibiotics/

Agree, looks positive for a return to trading at the end of the month. Would like to know how much cash they are left with. They have some interesting stuff in the pipeline and hope they have sufficient funds to just get on now and put this sorry episode behind them.

Evening Dibs, Yes, it's only when you have time to read and fully digest these RNS's that you appreciate what's going on here.

The next major conference is the World CDx, Boston on the 17th to 19th October. Interesting to note that Professor Stuart Martin, University of Maryland will be speaking on behalf of Angle PLC. His research was the subject of one of this morning's RNS's - PARSORTIXTM SYSTEM CENTRAL TO POTENTIAL NEW ANALYTICAL PROTOCOL FOR IDENTIFYING DRUGS THAT MAY ARREST METASTASIS. I was wondering whether more results from the ovarian study might be presented at this conference - guess we'll have to wait and see. http://world-cdx.com/about/speakers/ http://world-cdx.com/about/agenda/ https://investegate.co.uk/angle-plc--agl-/rns/potential-new-analytical-protocol-using-parsortix/201710090701010018T/

Good to see Parsortix being used by commercial customers rather than purely academic, with presentations from Bayer and Synexa Life Sciences.

Wow - an impressive set of RNS's this morning. "ANGLE's ParsortixTM system was showcased in 8 different poster presentations and five plenary presentations (It was also referenced by speakers in multiple other presentations)" Was particularly struck by the research from Heinrich Heine University demonstrating that they have managed to grow circulating tumour cells captured by the Parsortix system in the lab.

I understood that the FDA's approval for CellSearch was based on evidence from clinical trials - just like any other product.

Is this new research? I don't recall any previous research into endometrial cancer:- "Additionally, a novel liquid biopsy protocol for the identification and enumeration of circulating tumour cells (CTCs) in patients with advanced stage EC has been developed using the Parsortix device. The efficacy of this device has been compared to the Food and Drug Administration (FDA) approved CellSearch platform for enumeration of CTCs. The Parsortix device has been shown to be more efficient at enumerating CTCs and good inter-observer variability between users has been demonstrated. http://discovery.ucl.ac.uk/1558772/

That might be interesting :)

MissBMW, Not that I know of, but would be grateful for any feedback if you get the chance. Will be interesting to see what comes out of the ATCT conference in Rhodes. I guess at the very least we'll see some new research using Parsortix.

Proactive interview with AN https://www.youtube.com/watch?v=jpbH-Sa3gWo

Wonder whether we'll see an RNS in the morning announcing that Redx will resume trading?

Ergomed Signs First Commercialisation Deal for Haemostatix Products - Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential Bodes well for PeproStat phase IIb trial results due in Q4 https://investegate.co.uk/ergomed-plc--ergo-/rns/commercialisation-deal-on-haemostatix-products/201709270700058982R/

Nice coverage in article below:- https://www.mddionline.com/qiagen-partners-cell-diagnostics-company

Good news and a very sensible move.

Courtesy of ridicule on ADVFN - an article in today's Telegraph says that Angle have struck a co-marketing deal with Qiagen:- "A British biotech minnow developing blood tests to diagnose cancer has struck a sales deal with a German ­genetics giant listed in New York that it hopes will unlock access to the lucrative US market. " http://www.telegraph.co.uk/business/2017/09/11/british-biotech-behind-blood-tests-cancer-strikes-deal-german/